Dementia

#Alchemab Therapeutics #Amyotrophic lateral sclerosis (ALS) #Dementia #Eli Lilly #Neuroscience

ALS drug licensing agreement confirmed

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. The transaction is worth up to a total of $415 million, including an undisclosed upfront payment, potential discovery, development, and commercialisation… Read More

#Business & Investment #News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Dementia #Therapeutic Antibodies #UK Dementia Research Institute

Scientists discover why Alzheimer’s drugs are effective

Scientists in the UK and Belgium have discovered new insights into how four different anti-amyloid drugs interact with amyloid beta protein, revealing why the drugs have had varying levels of success at treating Alzheimer’s disease. Amyloid beta is one of the toxic proteins which builds up in clumps… Read More

#News #Trending News

Map of Iceland
#Alzheimer's #Arctic Therapeutics #Dementia #Dermatology #Financing #Neuroscience

Scale-up explores anti-amyloid treatments for dementia

Icelandic drug discovery and development company Arctic Therapeutics (ATx) has announced the successful closing of a €26.5 million oversubscribed Series A financing from a syndicate of international investors.  The syndicate includes the EIC Fund, Iceland's largest privately-held investment firm Kaldbakur, Investcorp-backed Sanos Group, Swiss-based Cerebrum DAO, The Lurie Family Foundation,… Read More

#Business & Investment #News

#Dementia #Genetics / genomics #Neurodegenerative disorders #Vesper Bio

POC study initiated for frontotemporal dementia treatment

Vesper Bio has initiated a Phase Ib/IIa Proof of Concept (POC) study of its lead candidate VES001 for frontotemporal dementia. The SORT-IN-2 study will evaluate VES001 in patients with mutations in their progranulin-coding gene (GRN), which are causal for FTD(GRN). FTD(GRN) is an early onset degenerative brain disease which is… Read More

#News

#Dementia #Funding #Investment #Parkinson's #UK Dementia Research Institute

£20m funding offered to advance breakthroughs in dementia research

The UK Dementia Research Institute has received major new government funding to boost translational research into dementia and related neurodegenerative conditions such as Parkinson’s and motor neuron disease. The UK-wide research institute will receive an initial £20 ($25.9) million from the National Institute for Health and… Read More

#News

CT scans of the brain
#Alzheimer's #Clinical trial #Dementia #UK

Accelerator to boost dementia clinical trial participation in UK 

A new initiative hopes to increase the number of people participating in dementia clinical trials in the UK, aiming to identify tens of thousands of potential trial participants.  The new ‘Dementia Trials Accelerator’ initiative hopes to address pharma-identified roadblocks to the delivery of commercial clinical trials in… Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

New DDW Highlights podcast: 17 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week, DDW has opened registrations for its webinar ‘The latest… Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

New DDW Highlights vodcast: 17 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week, DDW has opened… Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

This week in drug discovery (9-13 September) 

News round-up for 9-13 September by DDW Senior Digital Content Editor Diana Spencer. This week, DDW has opened registrations for its webinar ‘The latest advancements driving neuroscience drug discovery research’, so our news highlights focus on developments in neuroscience, including a novel drug that has… Read More

#News

Dementia
#Dementia #Genetics / genomics #Neurodegenerative disorders #Phase I trial #Vesper Bio

Study offers possible treatment for frontotemporal dementia

Vesper Bio has completed a Phase I study for its lead candidate, VES001, a potentially disease-modifying treatment for frontotemporal dementia patients with mutations in the progranulin gene (FTD(GRN)). Frontotemporal dementia is the most common cause of dementia in people under the age of 60. FTD(GRN), which… Read More

#Editor's Choice #News

Jigsaw puzzle of the brain
#Alzheimer's #Dementia #Diabetes #GLP-1 #Novo Nordisk #Phase II trial #Weight loss

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language… Read More

#News #Trending News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

New DDW Highlights podcast: 29 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy,… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

This week in drug discovery (22-26 July) 

News round-up for 22-26 July by DDW Senior Digital Content Editor Diana Spencer. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing… Read More

#News

Older adult receiving vaccine
#Dementia #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Shingles #University of Oxford

New shingles vaccine found to reduce risk of dementia

New evidence indicates that a new shingles vaccine is more protective against dementia compared to the previous shingles vaccine, which was also reported to reduce dementia rates. It is also more protective than vaccines against other infections. A study of more… Read More

#News

MRI of the brain
#AviadoBio #Dementia #Gene therapy #Neurodegenerative disorders #Phase II trial

Gene therapy trial starts in early-onset dementia

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. ASPIRE-FTD is evaluating investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). The study is also recruiting in Europe with… Read More

#News

Neurodegenerative disorders
#Dementia #Drug repurposing #Neurodegenerative disorders #University of Iowa

Drugs for enlarged prostate could prevent neurodegeneration

A new study suggests that certain drugs commonly used to treat enlarged prostate may also decrease the risk for dementia with Lewy bodies (DLB) and potentially other neurodegenerative diseases. This observational finding mirrors previous work by the University of Iowa (UI) Health Care team that links… Read More

#News